Filters
Results 1 - 10 of 612
Results 1 - 10 of 612.
Search took: 0.02 seconds
| Sort by: date | relevance |
[en] The requirements for the routine use of radioimmunoscintigraphy (RIS) of cancer in clinical practice are realised and discussed. Imaging quality, performance, feasibility and clinical utility of these examinations are the most important factors to be considered. The results obtained so far by the study of a large number of patients are very good and it seems important, for the development of these methods to widen the field of clinical applications both with new prospective trials and with extensive use of RIS in daily routine. (author). 33 refs.; 1 fig.; 10 tabs
Source
Baum, R.P.; Hoer, Gustav (University Medical Center, Frankfurt (Germany). Department of Nuclear Medicine); Cox, P.H. (Dr. Daniel Den Hoed Clinic, Rotterdam (Netherlands). Department of Nuclear Medicine); Buraggi, G.L. (National Tumour Institute, Milan (Italy). Nuclear Medicine Division); Developments in Nuclear Medicine; v. 19; 195 p; ISBN 0-7923-1424-7; 
; 1991; p. 15-30; Kluwer; Dordrecht (Netherlands); International Symposium, Post Congress Meeting of the German Nuclear Medicine Congress; Frankfurt am Main (Germany); Mar 1990
; 1991; p. 15-30; Kluwer; Dordrecht (Netherlands); International Symposium, Post Congress Meeting of the German Nuclear Medicine Congress; Frankfurt am Main (Germany); Mar 1990
[en] Short communication
Journal
[en] Molecular targeting may be defined as the specific concentration of a diagnostic or therapeutic tracer by its interaction with a molecular species that is distinctly present or absent in a disease state. Monoclonal antibody (mAb) is one of the successful agents for targeted therapy in cancer. To enhance the therapeutic effect. the concept of targeting radionuclides to tumors using radiolabeled mAbs against tumor-associated antigens, radioimmunotherapy, was proposed. The efficacy of radioimmunotherapy, however, has to be further optimized. Several strategies to improve targeting of tumors with radiolabeled mAbs have been developed, such as the use of mAb fragments, the use of high-affinity mAbs, the use of labeling techniques that are stable in vivo, active removal of the radiolabeled mAb from the circulation, and pretargeting strategies. Until now, however, there are many kinds of obstacles to be solved in the use of mAb for the targeted therapy. Major technical challenges to molecular targeting are related to the rapid and specific delivery of tracers to the target, the elimination of unwanted background activity, and the development of more specific targets to create a cytocidal effect. Further development of this field will be determined by success in solving these challenges
Journal
Nuclear Medicine and Molecular Imaging; ISSN 1975-129X; ; v. 40(2); p. 74-81
; v. 40(2); p. 74-81
[en] Published in summary form only
Journal
| 1 | 2 | 3 | Next |